Home/Pipeline/AMCHEPRY

AMCHEPRY

Parkinson's Disease

ApprovedRecently approved in Japan (Mar 2026)

Key Facts

Indication

Parkinson's Disease

Phase

Approved

Status

Recently approved in Japan (Mar 2026)

Company

Sumitomo Dainippon Pharma

About Sumitomo Dainippon Pharma

A Japanese pharmaceutical company developing innovative therapies in neuroscience, oncology, and regenerative medicine, with a focus on small molecules and iPS cell-derived cell therapies.

View full company profile

Therapeutic Areas

Neuroscience Oncology Rare Disease

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active